MGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MeiraGTx Holdings PLC (MGTX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong revenue growth, promising pipeline, and positive regulatory developments outweigh the short-term risks. The current pre-market price of $9.48 offers an attractive entry point given the company's long-term potential.
The technical indicators are moderately positive. The MACD is above 0 and positively contracting, suggesting bullish momentum. The RSI is neutral at 47.437, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at $8.934, and resistance is at $11.303. The stock is trading near support levels, which could provide a good entry point.
FDA Breakthrough Therapy Designation for AAV2-hAQP1, a key late-stage asset.
Hedge funds significantly increasing their positions (869.70% increase in buying).
Positive news on acquiring bota-vec from Johnson & Johnson and plans for a $100 million equity raise to fund its launch.
Strong revenue growth in Q4 2025 (252.33% YoY).
Decline in net income (-138.30% YoY) and EPS (-138.00% YoY) in Q4
Stock trend analysis shows a potential short-term decline (-2.75% in the next week, -3.1% in the next month).
In Q4 2025, revenue increased by 252.33% YoY to $75.36 million, indicating strong growth. However, net income dropped by -138.30% YoY to $15.08 million, and EPS fell by -138.00% YoY to $0.19. Gross margin improved significantly to 99.37%, up 121.76% YoY, reflecting operational efficiency.
Analysts are generally positive on MGTX. Evercore ISI maintains an Outperform rating with a price target of $18. BofA raised its price target to $16 from $14, citing meaningful regulatory progress. Piper Sandler lowered its target to $26 from $30 but remains Overweight, highlighting the promising pipeline and upcoming catalysts.
